vs

Side-by-side financial comparison of Black Stone Minerals, L.P. (BSM) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $95.2M, roughly 1.6× Black Stone Minerals, L.P.). Black Stone Minerals, L.P. runs the higher net margin — 75.9% vs -5.5%, a 81.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -8.7%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -9.7%).

Black Stone Minerals, L.P., or Black Stone Minerals, is a Houston, Texas-based oil and natural gas corporation.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

BSM vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.6× larger
TARS
$151.7M
$95.2M
BSM
Growing faster (revenue YoY)
TARS
TARS
+137.1% gap
TARS
128.4%
-8.7%
BSM
Higher net margin
BSM
BSM
81.4% more per $
BSM
75.9%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-9.7%
BSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BSM
BSM
TARS
TARS
Revenue
$95.2M
$151.7M
Net Profit
$72.2M
$-8.4M
Gross Margin
Operating Margin
78.6%
-5.3%
Net Margin
75.9%
-5.5%
Revenue YoY
-8.7%
128.4%
Net Profit YoY
55.8%
63.8%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BSM
BSM
TARS
TARS
Q4 25
$95.2M
$151.7M
Q3 25
$105.2M
$118.7M
Q2 25
$106.7M
$102.7M
Q1 25
$115.3M
$78.3M
Q4 24
$104.3M
$66.4M
Q3 24
$103.2M
$48.1M
Q2 24
$115.2M
$40.8M
Q1 24
$116.8M
$27.6M
Net Profit
BSM
BSM
TARS
TARS
Q4 25
$72.2M
$-8.4M
Q3 25
$91.7M
$-12.6M
Q2 25
$120.0M
$-20.3M
Q1 25
$15.9M
$-25.1M
Q4 24
$46.3M
$-23.1M
Q3 24
$92.7M
$-23.4M
Q2 24
$68.3M
$-33.3M
Q1 24
$63.9M
$-35.7M
Operating Margin
BSM
BSM
TARS
TARS
Q4 25
78.6%
-5.3%
Q3 25
89.5%
-12.2%
Q2 25
-21.6%
Q1 25
14.9%
-33.5%
Q4 24
45.6%
-36.8%
Q3 24
90.2%
-52.3%
Q2 24
59.5%
-81.6%
Q1 24
54.8%
-136.5%
Net Margin
BSM
BSM
TARS
TARS
Q4 25
75.9%
-5.5%
Q3 25
87.2%
-10.6%
Q2 25
112.5%
-19.8%
Q1 25
13.8%
-32.1%
Q4 24
44.4%
-34.8%
Q3 24
89.9%
-48.7%
Q2 24
59.3%
-81.6%
Q1 24
54.7%
-129.4%
EPS (diluted)
BSM
BSM
TARS
TARS
Q4 25
$-0.17
Q3 25
$-0.30
Q2 25
$-0.48
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BSM
BSM
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$1.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
Total Assets
$1.3B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BSM
BSM
TARS
TARS
Q4 25
$1.5M
$417.3M
Q3 25
$2.9M
$401.8M
Q2 25
$2.5M
$381.1M
Q1 25
$2.4M
$407.9M
Q4 24
$2.5M
$291.4M
Q3 24
$21.0M
$317.0M
Q2 24
$26.7M
$323.6M
Q1 24
$40.5M
$298.5M
Total Debt
BSM
BSM
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
BSM
BSM
TARS
TARS
Q4 25
$343.4M
Q3 25
$335.1M
Q2 25
$332.6M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$237.5M
Q2 24
$252.2M
Q1 24
$275.2M
Total Assets
BSM
BSM
TARS
TARS
Q4 25
$1.3B
$562.2M
Q3 25
$1.3B
$534.6M
Q2 25
$1.3B
$495.0M
Q1 25
$1.2B
$500.8M
Q4 24
$1.2B
$377.0M
Q3 24
$1.2B
$376.3M
Q2 24
$1.2B
$376.8M
Q1 24
$1.2B
$349.3M
Debt / Equity
BSM
BSM
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BSM
BSM
TARS
TARS
Operating Cash FlowLast quarter
$65.1M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BSM
BSM
TARS
TARS
Q4 25
$65.1M
$19.3M
Q3 25
$99.8M
$18.3M
Q2 25
$80.5M
$-29.4M
Q1 25
$64.8M
$-20.7M
Q4 24
$91.0M
$-22.2M
Q3 24
$93.2M
$-8.7M
Q2 24
$100.4M
$-14.4M
Q1 24
$104.5M
$-37.8M
Free Cash Flow
BSM
BSM
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
BSM
BSM
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
BSM
BSM
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
BSM
BSM
TARS
TARS
Q4 25
0.90×
Q3 25
1.09×
Q2 25
0.67×
Q1 25
4.07×
Q4 24
1.96×
Q3 24
1.01×
Q2 24
1.47×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BSM
BSM

Oil Reserves$46.4M49%
Natural Gas Reserves$44.1M46%
Real Estate$4.7M5%

TARS
TARS

Segment breakdown not available.

Related Comparisons